A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
allow for the personal importation of safe and affordable 
drugs from approved pharmacies in Canada. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Safe and Affordable 
4
Drugs from Canada Act of 2021’’. 
5
SEC. 2. SAFE AND AFFORDABLE DRUGS FROM CANADA. 
6
Chapter VIII of the Federal Food, Drug, and Cos-
7
metic Act (21 U.S.C. 381 et seq.) is amended by adding 
8
at the end the following: 
9
17:42 Feb 24, 2021
H832
2 
•HR 832 IH
‘‘SEC. 810. IMPORTATION BY INDIVIDUALS OF PRESCRIP-
1
TION DRUGS FROM CANADA. 
2
‘‘(a) IN GENERAL.—Notwithstanding any other pro-
3
vision of this Act, not later than 180 days after the date 
4
of enactment of this section, the Secretary shall promul-
5
gate regulations permitting individuals to safely import 
6
into the United States a prescription drug described in 
7
subsection (b). 
8
‘‘(b) PRESCRIPTION DRUG.—A prescription drug de-
9
scribed in this subsection— 
10
‘‘(1) is a prescription drug that— 
11
‘‘(A) is purchased from an approved Cana-
12
dian pharmacy; 
13
‘‘(B) is dispensed by a pharmacist licensed 
14
to practice pharmacy and dispense prescription 
15
drugs in Canada; 
16
‘‘(C) is purchased for personal use by the 
17
individual, not for resale, in quantities that do 
18
not exceed a 90-day supply; 
19
‘‘(D) is filled using a valid prescription 
20
issued by a physician licensed to practice in a 
21
State in the United States; and 
22
‘‘(E) has the same active ingredient or in-
23
gredients, route of administration, dosage form, 
24
and strength as a prescription drug approved 
25
by the Secretary under chapter V; and 
26
17:42 Feb 24, 2021
H832
3 
•HR 832 IH
‘‘(2) does not include— 
1
‘‘(A) a controlled substance (as defined in 
2
section 102 of the Controlled Substances Act 
3
(21 U.S.C. 802)); 
4
‘‘(B) a biological product (as defined in 
5
section 351 of the Public Health Service Act 
6
(42 U.S.C. 262)); 
7
‘‘(C) an infused drug (including a peri-
8
toneal dialysis solution); 
9
‘‘(D) an intravenously injected drug; 
10
‘‘(E) a drug that is inhaled during surgery; 
11
‘‘(F) a parenteral drug; 
12
‘‘(G) a drug manufactured through one or 
13
more biotechnology processes, including— 
14
‘‘(i) a therapeutic DNA plasmid prod-
15
uct; 
16
‘‘(ii) a therapeutic synthetic peptide 
17
product of not more than 40 amino acids; 
18
‘‘(iii) a monoclonal antibody product 
19
for in vivo use; and 
20
‘‘(iv) a therapeutic recombinant DNA- 
21
derived product; 
22
‘‘(H) a drug required to be refrigerated at 
23
any time during manufacturing, packing, proc-
24
essing, or holding; or 
25
17:42 Feb 24, 2021
H832
4 
•HR 832 IH
‘‘(I) a photoreactive drug. 
1
‘‘(c) APPROVED CANADIAN PHARMACY.— 
2
‘‘(1) IN
GENERAL.—In this section, an ap-
3
proved Canadian pharmacy is a pharmacy that— 
4
‘‘(A) is located in Canada; and 
5
‘‘(B) that the Secretary certifies— 
6
‘‘(i) is licensed to operate and dis-
7
pense prescription drugs to individuals in 
8
Canada; and 
9
‘‘(ii) meets the criteria under para-
10
graph (3). 
11
‘‘(2) PUBLICATION
OF
APPROVED
CANADIAN 
12
PHARMACIES.—The Secretary shall publish on the 
13
internet website of the Food and Drug Administra-
14
tion a list of approved Canadian pharmacies, includ-
15
ing the internet website address of each such ap-
16
proved Canadian pharmacy, from which individuals 
17
may purchase prescription drugs in accordance with 
18
subsection (a). 
19
‘‘(3) ADDITIONAL
CRITERIA.—To be an ap-
20
proved Canadian pharmacy, the Secretary shall cer-
21
tify that the pharmacy— 
22
‘‘(A) has been in existence for a period of 
23
at least 5 years preceding the date of such cer-
24
tification and has a purpose other than to par-
25
17:42 Feb 24, 2021
H832
5 
•HR 832 IH
ticipate in the program established under this 
1
section; 
2
‘‘(B) operates in accordance with phar-
3
macy standards set forth by the provincial 
4
pharmacy rules and regulations enacted in Can-
5
ada; 
6
‘‘(C) has processes established by the phar-
7
macy, or participates in another established 
8
process, to certify that the physical premises 
9
and data reporting procedures and licenses are 
10
in compliance with all applicable laws and regu-
11
lations, and has implemented policies designed 
12
to monitor ongoing compliance with such laws 
13
and regulations; 
14
‘‘(D) conducts or commits to participate in 
15
ongoing and comprehensive quality assurance 
16
programs and implements such quality assur-
17
ance measures, including blind testing, to en-
18
sure the veracity and reliability of the findings 
19
of the quality assurance program; 
20
‘‘(E) agrees that laboratories approved by 
21
the Secretary shall be used to conduct product 
22
testing to determine the safety and efficacy of 
23
sample pharmaceutical products; 
24
17:42 Feb 24, 2021
H832
6 
•HR 832 IH
‘‘(F) has established, or will establish or 
1
participate in, a process for resolving grievances 
2
and will be held accountable for violations of es-
3
tablished guidelines and rules; 
4
‘‘(G) does not resell products from online 
5
pharmacies located outside Canada to cus-
6
tomers in the United States; and 
7
‘‘(H) meets any other criteria established 
8
by the Secretary.’’. 
9
Æ 
17:42 Feb 24, 2021
H832
